Semicarbazide-Sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model

American Journal of Physiology - Renal Physiology

Volumn 307, Issue 8, 2014, Pages F908-F916

  Wong, May ^a   Saad, Sonia ^a   Zhang, Jie ^a   Gross, Simon ^a   Jarolimek, Wolfgang ^b   Schilter, Heidi ^b   Chen, Jason A ^a   Gill, Anthony J ^a   Pollock, Carol A ^a   Wong, Muh Geot ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Frenchs Forest   (Australia)

Author keywords

Anti inflammatory; Semicarbazide sensitive amine oxidase; Tubulointerstitial fibrosis; Unilateral ureteral obstruction murine model

Indexed keywords

3 NITROTYROSINE; AMINE OXIDASE (COPPER CONTAINING); ANTIFIBROTIC AGENT; COLLAGEN TYPE 4; FIBRONECTIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PXS 4728A; SEMICARBAZIDE SENSITIVE AMINE OXIDASE INHIBITOR; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; CARBAMYLHYDRAZINE; ENZYME INHIBITOR; SEMICARBAZIDE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; KIDNEY FIBROSIS; LEUKOCYTE; MACROPHAGE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; URETER OBSTRUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; ENZYMOLOGY; FIBROSIS; KIDNEY; KIDNEY DISEASES; PATHOLOGY;

AMINE OXIDASE (COPPER-CONTAINING); ANIMALS; BENZIMIDAZOLES; BENZOATES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FIBROSIS; KIDNEY; KIDNEY DISEASES; MICE, INBRED C57BL; SEMICARBAZIDES; URETERAL OBSTRUCTION;

EID: 84908076425     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00698.2013     Document Type: Article

References (28)

1. Anders HJ, Vielhauer V, Schlöndorff D. Chemokines and chemokine receptors are involved in the resolution and progression of renal disease. Therapeutic implications. Kidney Int 63: 401-415, 2003.
2. Bohle A, Christ H, Grund K, Mackensen S. The role of the interstitium of the renal cortex in renal disease. Contrib Nephrol 16: 109-114, 1979.
3. Bohle A, Mackensen-Haen S, von Gise H. Significance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney: a morphometric contribution. Am J Nephrol 7: 421-433, 1987.
4. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 12: 353-365, 2005.
5. Foot JS, Yow TT, Schilter H, Buson A, Deodhar M, Findlay AD, Guo L, McDonald IA, Turner CI, Zhou W, Jarolimek W. PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo. J Pharmacol Exp Ther 347: 365-374, 2013.
6. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O’Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P; VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369: 1892-1903, 2013.
7. Gella A, Sole M, Bolea I, Ventriglia M, Siotto M, Durany N, Squitti R, Unzeta M. A comparison between radiometric and fluorimetric methods for measuring SSAO activity. J Neural Transm 120: 1015-1018, 2013.
8. Jalkanen S, Salmi M. VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation. Arterioscler Thromb Vasc Biol 28: 18-16, 2008.
9. Kusunoki H, Taniyama Y, Azuma J, Iekushi K, Sanada F, Otsu R, Iwabayashi M, Okayama K, Rakugi H, Morishita R. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptorgamma/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade. Hypertension 59: 308-316, 2012.
10. Lee SB, Kalluri R. Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl: 119: S22-S26, 2010.
11. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 69: 213-217, 2006.
12. McEwen CM, Cohen JD. An amine oxidase in normal human serum. J Lab Clin Med 62: 766-776, 1963.
13. Mercier N, Osborne-Pellegrin M, El Hadri K, Kakou A, Labat C, Loufrani L, Henrion D, Challande P, Jalkanen S, Fève B, Lacolley P. Carotid arterial stiffness, elastic fibre network and vasoreactivity in semicarbazide-sensitive amine-oxidase null mouse. Cardiovasc Res 72: 349-357, 2006.
14. Nath K. The tubulointerstitium in progressive renal disease. Kidney Int 54: 992-994, 1998.
15. O’Rourke AM, Wang EY, Miller A, Podar EM, Scheyhing K, Huang L, Kessler C, Gao H, Ton-Nu HT, Macdonald MT, Jones DS, Linnik MD. Anti-inflammatory effects of LJP 1586 (Z-3-fluoro-2-(4-methoxy benzyl)allylamine hydrochloride), an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity. J Pharmacol Exp Ther 324: 867-875, 2008.
16. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367: 2204-2214, 2012.
17. Poirier B, Lannaud-Bournoville M, Conti M, Bazin R, Michel O, Bariéty J, Chevalier J, Myara I. Oxidative stress occurs in absence of hyperglycaemia and inflammation in the onset of kidney lesions in normotensive obese rats. Nephrol Dial Transplant 15: 467-476, 2000.
18. Prodjosudjadi W, Gerritsma JS, Klar-Mohamad N, Gerritsen AF, Bruijn JA, Daha MR, van Es LA. Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int 48: 1477-1486, 1995.
19. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 116: 288-296, 2006.
20. Salmi M, Yegutkin G, Lehvonen R, Koskinen K, Salminen T, Jalkanen S. A cell surface amine oxidase directly controls lymphocyte migration. Immunity 14: 265-276, 2001.
21. Sean Eardley K, Cockwell P. Macrophages and progressive tubulointerstitial disease. Kidney Int 68: 437-455, 2005.
22. Smith D, Salmi M, Bono P, Hellman J, Leu T, Jalkanen S. Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule. J Exp Med 188: 17-27, 1998.
23. Vaughan ED, Jr., Marion D, Poppas DP, Felsen D. Pathophysiology of unilateral ureteral obstruction: studies from Charlottesville to New York. J Urol 172: 2563-2569, 2004.
24. Vilayur E, Harris D. Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol 5: 375-383, 2009.
25. Wolf G, Jocks T, Zahner G, Panzer U, Stahl RA. Existence of a regulatory loop between MCP-1 and TGF in glomerular immune injury. Am J Physiol Renal Physiol 283: F1075-F1084, 2002.
26. Wong MY, Saad S, Pollock C, Wong MG. Semicarbazide-sensitive amine oxidase and kidney disease. Am J Physiol Renal Physiol 305: F1637-F1644, 2013.
27. Yu C, Wang F, Jin C, Wu X, Chan WK, McKeehan WL. Increased carbon tetrachloride-induced liver injury and fibrosis in FGFR4-deficient mice. Am J Pathol 161: 2003-2010, 2002.
28. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 12: 121-127, 2000.